View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 18, 2020updated 16 Feb 2022 6:27am

Cerus Endovascular gets CE Mark for Contour Neurovascular System

US-based medical device company Cerus Endovascular has secured CE Mark approval for Contour Neurovascular System, intended to treat intracranial aneurysms.

US-based medical device company Cerus Endovascular has secured CE Mark approval for Contour Neurovascular System, intended to treat intracranial aneurysms.

A mesh braid across the neck of the aneurysm sac, the Contour Neurovascular System offers a combination of flow diversion and flow disruption through one device implant.

Furthermore, designed to be self-anchored for stability, the system can target the neck of the aneurysm, away from the vulnerable dome.

The company expects to begin commercial sales, through a controlled market release across the European Union (EU), during the second quarter of 2020.

The firm secured the CE Mark approval based on data generated from its two EU studies analysing the safety and efficacy of the System, focusing on unruptured intracranial aneurysms.

The latest study completed last year took place at six sites in Germany, Austria and Denmark.

The earlier study took place in four sites in the UK and Hungary.

Data from the first study was presented at several scientific conferences early this year, while data from the second study will be presented later this year.

Cerus Endovascular president Dr Stephen Griffin said: “As our clinical data experience grows, and more physicians use the System, results continue to be compelling – providing additional confirmation that the Contour Neurovascular System delivers an important clinical option and represents a new, and potentially disruptive, standalone solution for the treatment of bifurcated saccular intracranial aneurysms compared to currently available technologies.

“Importantly, physicians who have used the System have highlighted the benefits inherent in its unique simplicity, including a simple sizing approach of the device to the aneurysm width, ease of deliverability and controlled deployment.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU